Twist hits breakeven as AI demand surges, but price matters
- Q4 FY26 revenue rose 28% to $126.6 million, and the company hit adjusted EBITDA breakeven.
- AI drug discovery revenue grew 175% for the year, reaching $59.1 million.
- NGS applications re-accelerated to 24% growth, clearing up a key investor concern.
- A heavy $75 million capital expenditure plan for fiscal 2027 will create new margin headwinds.
- The valuation remains very demanding, leaving little room for error if capacity investments drag on cash.
Breakeven achieved, but the investment cycle continues
Twist delivered a highly positive close to fiscal 2026. Q4 revenue grew 28% year over year to $126.6 million. More importantly, the company achieved its long-standing goal of reaching positive adjusted EBITDA, posting a $2.2 million gain. The bull case is now grounded in proven operational leverage and massive secular tailwinds from AI drug discovery, which saw revenue surge 175% for the full year.
Next-generation sequencing (NGS) applications also successfully re-accelerated to 24% growth in the quarter. This provides a stable, high-growth second engine alongside the fast-expanding DNA synthesis business. Management expects AI-driven revenue to reach $100 million in fiscal 2027, driven by customers moving from pilot programs to recurring, multi-million dollar discovery orders.
The bear case now centers on execution risk during a period of heavy capacity expansion. The company is guiding for $75 million in capital expenditures for fiscal 2027 to build out capacity ahead of demand. This will result in a 2 to 3 percent gross margin headwind due to depreciation. If Twist fails to fill this new capacity with the anticipated demand, profitability will suffer and the company could return to burning cash.
A DNA factory for drug builders
Twist makes money by using its silicon-based DNA synthesis platform to produce synthetic DNA at high scale. Customers buy genes, gene fragments, oligo pools, antibody discovery work, and sequencing workflow tools. The basic idea is simple: scientists design DNA on a computer, Twist builds it, and the customer uses it in research, diagnostics, or drug discovery.
The higher-value part of the model involves moving customers from basic DNA orders into full workflows. AI drug discovery companies are a key example. Many of them need a fast loop: design a molecule, build the DNA, test the protein, learn from the result, then repeat. Twist sells into several steps of that loop and recently launched cell-free protein screening to speed up the process.
The model breaks if speed, quality, or cost advantages fade. It also breaks if newer demand is more one-time than repeat. That is why the mix of AI revenue matters. Recurring discovery work is much better than large model-building orders that do not repeat.
From genes to cancer panels
Synthetic genes and gene fragments
These are core DNA building blocks for research and drug discovery. They help fill the platform and bring customers into the broader product set.
Protein solutions and antibody discovery
This area helps researchers move from DNA design to protein testing. It includes the new Twist Express Screening Antibodies, which deliver proteins in just five days.
NGS applications
Twist sells tools such as target enrichment panels for clinical and research workflows. This segment re-accelerated to 24% growth in the latest quarter.
MRD Express
A newly launched product offering individualized tumor-informed panels manufactured at scale, designed specifically for the cancer monitoring market.
Oligo pools
Large sets of short DNA sequences used in experiments and screening. They support the high-throughput side of Twist's platform.
Two engines, growing fast
Segment mix is from Q4 FY26, the quarter ended September 30, 2026. NGS applications accounted for roughly 52% of revenue, while DNA synthesis and protein solutions accounted for 48%. Both segments grew over 20% year over year.
What could break the thesis
Heavy capacity investments pressure margins
High impact · Medium oddsManagement guided for $75 million in capital expenditures for fiscal 2027. This buildout will cause a 2 to 3 percent gross margin headwind due to depreciation. If demand fails to fill this new capacity, profitability will suffer.
AI orders prove lumpy
High impact · Medium oddsAI-enabled drug discovery is now a massive growth engine, hitting $59.1 million in fiscal 2026. The open question is whether future revenue is recurring discovery work or large, one-time model-training orders.
MRD Express adoption lags
Medium impact · Medium oddsMRD Express is a key new NGS product for cancer monitoring. The product is commercially launched, but the revenue profile and customer adoption curve are still unproven in a competitive diagnostic market.
Less diversification after data storage spinout
Medium impact · Low oddsTwist spun out its DNA data storage work into Atlas Data Storage in May 2025. The filing risk is that Twist may not receive all expected benefits if Atlas does not commercialize the technology well.
In one breath
What does Twist Bioscience actually sell?
Twist sells synthetic DNA products, protein and antibody services, and tools used in next-generation sequencing. Its platform helps researchers and drug developers build and test biological designs faster.
Why is AI drug discovery important for Twist?
AI drug discovery companies need to test many designs in the lab. Twist can supply the DNA and related protein work that lets those companies run the design, build, test, learn cycle rapidly.
Is Twist Bioscience profitable?
The company reached adjusted EBITDA breakeven in Q4 FY26. However, heavy capital expenditure plans for fiscal 2027 mean the company will still face significant margin and cash flow pressures.
What is the biggest thing to watch next?
Watch whether the company can maintain adjusted EBITDA profitability throughout fiscal 2027 despite taking on $75 million in capital expenditures to build new capacity.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 15, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Diagnostics & Research companies
Companies near Twist Bioscience Corporation in Finn's Diagnostics & Research industry ranking.

